Vima Therapeutics is gearing up to launch a Phase 2 clinical trial this year to evaluate VIM0423, its potential first-in-class once-daily oral therapy for dystonia, or abnormal muscle tone, associated with Parkinson’s disease. Meanwhile, the first participant has been dosed in Stride Dystonia, a Phase 2…
